In the hospitals and clinics of eastern China, a fourteen-year reckoning has arrived: the antiretroviral drugs that once represented progress in the fight against HIV have, through decades of widespread use, taught the virus how to survive them. Researchers at Huzhou Central Hospital have documented drug resistance rates more than double the threshold the World Health Organization considers a public health emergency, while a newer generation of treatments achieves what the old ones cannot. The story is one medicine has told before — that solutions, left unchanged long enough, can become part o
China's HIV drug resistance surges as older antiretrovirals lose efficacy
Treatment failures in HIV patients using older regimens resulted in sustained viral replication and continued disease progression, with implications for transmission and mortality risk.
The virus had learned to survive the medications prescribed to suppress it
Mark
Why did China stick with these older drugs for so long if they're less effective?
Mimi
They were the standard when the program began in 2003, and they worked well enough at the time. Scale matters—treating millions of people means you don't change course lightly. But prolonged use of the same drug class creates exactly the pressure that leads to resistance.
Mark
So the virus learned to survive the medicine?
Mimi
Exactly. Every time the virus replicates in someone taking these drugs, there's a chance a mutation arises that lets it survive. Over twenty years, across millions of patients, those mutations accumulated and spread.
Mark
The newer drugs—dolutegravir—they achieved 100% suppression. That's remarkable.
Mimi
It is. But it's not magic. It's a different mechanism. The virus hasn't had two decades to adapt to it. The question is whether China moves now, before resistance to dolutegravir emerges the same way.
Mark
What happens to patients already on the failing regimens?
Mimi
That's the human cost. Their viral loads aren't suppressed. The virus keeps replicating. Disease progresses. They remain infectious. And if they're on a regimen the virus has learned to resist, switching drugs becomes more complicated.
Mark
Is this a China-specific problem?
Mimi
The scale and duration are specific to China's program, but the principle is universal. Any place that relies on a single drug class for too long will see this pattern emerge.
El Pulso
- More than one in five HIV patients in the study carried virus strains already resistant to their prescribed medications, a figure that doubles the WHO's threshold for public health alarm.
- Decades of relying on the same class of older antiretrovirals created sustained evolutionary pressure, and the virus responded by adapting — drug-resistant strains are now spreading between patients, not merely emerging within them.
- Patients on older efavirenz-based regimens failed to suppress the virus in up to one-third of cases, meaning sustained viral replication, accelerating disease, and ongoing transmission risk for a significant share of those in treatment.
- Newer integrase inhibitor-based therapy, by contrast, achieved complete virological suppression in every patient studied at 48 weeks — a clinical gap so wide it reframes the older drugs not as adequate but as actively harmful.
- Researchers are calling for immediate national transition to dolutegravir-based first-line therapy alongside baseline resistance testing, a shift that would require overhauling a program that has treated millions on the same protocol for over twenty years.
In the hospitals and clinics of eastern China, a fourteen-year reckoning has arrived: the antiretroviral drugs that once represented progress in the fight against HIV have, through decades of widespread use, taught the virus how to survive them. Researchers at Huzhou Central Hospital have documented drug resistance rates more than double the threshold the World Health Organization considers a public health emergency, while a newer generation of treatments achieves what the old ones cannot. The story is one medicine has told before — that solutions, left unchanged long enough, can become part of the problem — and it now calls China's national HIV program toward an overdue reckoning with its own success.
At Huzhou Central Hospital in Zhejiang Province, a fourteen-year study of HIV treatment outcomes has produced a troubling verdict: the drugs anchoring China's national HIV program since 2003 are failing at rates that now constitute a public health emergency.
Drawing on data from 635 patients tracked over more than a decade and a more recent surveillance sample of 268 individuals, researchers found that 22.4% of patients carried HIV strains resistant to their medications — more than double the World Health Organization's 10% threshold for transmitted drug resistance. The mechanism is not mysterious. China's prolonged, widespread reliance on non-nucleoside reverse transcriptase inhibitors created sustained evolutionary pressure, and the virus adapted. Drug-resistant strains are no longer just emerging within individual patients; molecular evidence suggests they are spreading between them.
The treatment outcome data sharpened the picture further. Patients on integrase strand transfer inhibitor-based therapy — a newer drug class — achieved complete virological suppression in 100% of cases at 48 weeks. Those on the older tenofovir, lamivudine, and efavirenz combination suppressed the virus in only 87.9% of cases. Patients on thymidine analogue regimens fared worst, with suppression rates between 67 and 78%. When viral load is not suppressed, disease progresses and transmission risk remains elevated.
Three factors independently predicted resistance among treatment-experienced patients: a prior history of virological failure, infection with the circulating recombinant strain 01_AE — which appeared in nearly a quarter of treatment-experienced sequences but was absent among treatment-naïve patients — and treatment with efavirenz-based rather than dolutegravir-based regimens. The older drugs were not merely less effective; they were selecting for resistance.
The researchers' call is direct: China should transition immediately to universal dolutegravir-based first-line therapy, paired with baseline genotypic resistance testing to identify resistance before a regimen is chosen. The drugs that once served millions well have reached the limit of what they can offer, and the evidence now points clearly toward what must replace them.
At Huzhou Central Hospital in Zhejiang Province, researchers spent fourteen years watching HIV treatment outcomes unfold. What they found was troubling: the older drugs that have anchored China's national HIV program since 2003 are failing at alarming rates, and the virus is evolving to resist them.
The data came from two sources. First, a longitudinal study tracking 635 patients from 2010 to 2023. Second, a surveillance snapshot of 268 treatment-experienced and treatment-naïve patients sampled between December 2024 and July 2025. When the researchers analyzed drug resistance mutations in the virus samples, they discovered that 22.4% of patients carried strains resistant to their medications. That figure exceeds the World Health Organization's 10% threshold for transmitted drug resistance—the point at which resistance becomes a public health problem.
The culprit is clear: China's reliance on non-nucleoside reverse transcriptase inhibitors, a class of older antiretrovirals that have been the backbone of first-line treatment for more than two decades. This prolonged, widespread use created sustained pressure on the virus to evolve around the drugs. The consequence is a population of patients whose HIV has learned to survive the medications prescribed to suppress it.
When the researchers compared treatment outcomes across different drug regimens, the gap was stark. Patients on integrase strand transfer inhibitor-based therapy—a newer class of drugs—achieved complete virological suppression in 100% of cases at 48 weeks. Those on the older combination of tenofovir, lamivudine, and efavirenz suppressed the virus in only 87.9% of cases. Patients on thymidine analogues paired with non-nucleoside reverse transcriptase inhibitors fared worst: 67 to 78% achieved suppression. The difference was statistically significant and clinically meaningful. When a patient's viral load is not suppressed, the virus continues replicating, disease progression accelerates, and the risk of transmission to others remains high.
A particular strain of HIV, circulating recombinant form 01_AE, tells part of the story. Among treatment-naïve patients—those never exposed to antiretrovirals—this strain was absent. But among treatment-experienced patients, it represented 24.2% of all sequences. The virus had shifted. The researchers found evidence of molecular transmission clustering, suggesting that drug-resistant strains were spreading between patients, not just emerging independently within individuals.
When the researchers analyzed which factors independently predicted drug resistance among treatment-experienced patients, three stood out. Prior virological failure—a history of the virus not being suppressed—increased the odds of resistance by a factor of 4.12. Infection with the 01_AE strain increased odds by 2.67. And being treated with efavirenz-based regimens rather than dolutegravir-based ones increased odds by 2.18. The message was embedded in the numbers: the older drugs were not only less effective; they were actively selecting for resistance.
The implications are urgent. China's HIV program has treated millions of patients with the same older regimens for over two decades. As resistance accumulates, treatment failures will multiply. The researchers argue for immediate transition to universal dolutegravir-based first-line therapy paired with baseline genotypic resistance testing—a way to identify resistance before choosing a regimen. It is a straightforward recommendation grounded in evidence: newer drugs work better, prevent resistance, and should replace the aging arsenal that once served the program well but can no longer be relied upon.
Citas Notables
These findings provide empirical justification for immediate transition to universal dolutegravir-based first-line therapy with baseline genotypic resistance testing— Study authors
Quieres la nota completa?
Lee el original en nature.com ↗
Health & Medicine